| VIVUS is a pharmaceutical company with approved therapies and one product candidate in clinical development. Qsymia® (phentermine and topiramate extended release) is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management. PANCREAZE®/ PANCREASE® MT (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. STENDRA® (avanafil) is approved by FDA for erectile dysfunction (ED) and by the European Commission under the trade name SPEDRA, for the treatment of ED in the European Union.VI-0106 (tacrolimus) is in clinical development and is being studied in patients with pulmonary arterial hypertension. We show 51 historical shares outstanding datapoints in our VVUS shares outstanding history coverage, used to compute VVUS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VVUS market cap history over the course of time is important for investors
interested in comparing VVUS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VVUS versus a peer is one thing; comparing
VVUS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VVUS can fluctuate over the course of history.
With this page we aim to empower investors researching VVUS by allowing them to research the VVUS market cap history.